

Product Datasheet

Zunsemetinib

Catalog No. **BP-02229** · CAS **1640282-42-3** · Form **free base** · Physical state **other** · Color **White to yellow** · Version **1.0** · Revision **2026-09-03**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target MAPKAPK2 (MK2)	Research area Inflammation/Immunology
---------------------------------	---

Molecular formula **C₂₅H₂₂ClF₂N₅O₃**

Molecular weight **513.9240**

STRUCTURE



DESCRIPTION

Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.

BIOLOGICAL ACTIVITY

Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.

SOLUBILITY

Soluble in DMSO 100 mg/mL

In vitro DMSO : 100 mg/mL

REFERENCES

- [1]. Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor
- [2]. Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine
- [3]. Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315-1325.